Blue Jet Healthcare

    BLUEJET
    Pharma
    ₹518.45
    Price as of 18 Nov 2026, 9:58 pm IST

    Market cap ₹8,993 Cr

    P/E
    32.34
    Day range
    ₹506.00 – ₹521.60
    52-week range
    ₹325.00 – ₹647.80
    Volume
    2.53 L
    Open
    ₹510.05
    Prev close
    ₹510.60

    Latest results · Q2 FY27(standalone)Revenue ₹376 Cr+127.1%Profit ₹103 Cr+96.6%Margin 27.3%YoY vs the same quarter last year

    1 red flag to read up on

    • medium

      Promoter holding falling

      73.15%, down 6.66 pts since 2025-12-31 · 30 Sept 2026

    From NSE and BSE filings. A flag is a reason to read the filing, not a rating.

    Research profile

    Composite 48 / 100

    Factor percentiles

    Value49
    Quality80
    Momentum54
    Low volatility10

    Derived metrics

    Earn. yield
    3.1%
    Graham no.
    ₹198.56
    vs Graham
    -61.7%
    ROE ÷ P/B
    4.5%
    12-1 mom.
    -11.7%
    Return / vol
    -0.26
    Magic Formula
    #161
    FCF yield
    1.3%

    Percentiles rank this stock against the other tracked stocks and change as they do. Scans describe where figures sit today. Hover a label for its definition. Not investment advice.

    Peer comparison

    All 68 in Pharma
    Largest Pharma companies tracked, with sector medians
    CompanyM-capP/EP/BROEROCEOPMD/ESales YoY
    Sun PharmaSUNPHARMA₹4.49 L Cr40.955.0314.8%21.0%29.0%0.04+11.9%
    Divi's LaboratoriesDIVISLAB₹2.93 L Cr87.1916.8816.2%22.0%43.0%0.00+35.4%
    Torrent PharmaTORNTPHARM₹1.75 L Cr77.889.6726.8%15.0%33.0%0.77+50.8%
    Apollo HospitalsAPOLLOHOSP₹1.27 L Cr56.4011.5522.6%17.0%16.0%0.77+23.0%
    Laurus LabsLAURUSLABS₹1.25 L Cr93.7219.8218.2%18.0%34.0%0.43+33.5%
    Zydus LifesciencesZYDUSLIFE₹1.20 L Cr28.724.3220.1%21.0%24.0%0.50+29.2%
    Dr. Reddy's LabsDRREDDY₹1.17 L Cr41.632.9711.6%13.0%20.0%0.19-1.5%
    Blue Jet HealthcareBLUEJET₹8,993 Cr32.344.4519.9%26.0%32.0%0.02+127.9%
    Sector median₹24,603 Cr43.685.4615.1%17.0%24.0%0.17+22.7%

    Sector as classified in the tracked universe; medians use every tracked Pharma company, and P/E only profitable ones. Tinted figures beat the median.

    Latest news

    Updated 1d ago

    Headlines about Blue Jet Healthcare from the last two weeks in the financial press. Stories belong to their publishers; Rajat Finance does not endorse them.

    Key metrics

    P/E (TTM)
    34.4
    Price / Book
    4.28
    ROE (FY26)
    19.9%
    ROCE (latest year)
    26%
    Dividend yield
    0.23%

    Moving averages (NSE)

    20-day
    ₹515.91
    Price above
    50-day
    ₹537.03
    Price below
    200-day
    ₹491.17
    Price above

    Charts & trends

    From company filings. Amounts in ₹ crore.

    Revenue 3Y CAGR
    +9.5%
    Profit 3Y CAGR
    +15.7%
    Revenue YoY (Sep 2026)
    +127.9%
    Profit YoY (Sep 2026)
    +98.1%
    Operating margin
    32.0%
    Net margin
    27.4%

    Revenue, profit & margin - quarterly

    ₹ crore; a loss shows red. Operating margin below, same periods.

    0 Cr100 Cr200 Cr300 Cr400 Cr
    • Revenue
    • Net profit

    Operating margin

    Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Sep 20260%25%50%

    Who owns the company

    % of equity by quarter, latest Sept 2026

    Dec '24Mar '25Jun '25Sept '25Dec '25Mar '26Jun '26Sept '260%25%50%75%100%
    • Promoter
    • Public
    • DII
    • FII

    Cash flows

    Where cash came from and went, by fiscal year (₹ crore)

    Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026-400 Cr-200 Cr0 Cr200 Cr400 Cr
    • Operating
    • Investing
    • Financing
    • Free cash flow

    Return on equity

    Net profit over shareholders' equity, by fiscal year

    FY21FY22FY23FY24FY25FY260%20%40%60%15% screen

    Equity vs debt

    Shareholders' equity against borrowings (₹ crore); the ratio below, same years.

    0 Cr1K Cr2K Cr3K Cr
    • Equity
    • Debt

    Debt to equity

    Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Sep 20260x0.5x1x

    Dividends per share

    ₹ by fiscal year of the ex-date; the latest year runs to date.

    FY26FY27₹0₹0.5₹1₹1.5

    Financial statements

    ₹ Crore
    Quarterly results, oldest period first, figures in rupees crore
    Line itemDec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
    Sales167184163208318340355165192235293376
    YoY Sales growth-1-15-9————-21-40-31-17—
    Expenses112131119139194200234111146163195257
    Operating Profit5553446912414012155477198119
    OPM %33%29%27%33%39%41%34%33%24%30%33%32%
    Other Income-39912131282413231526
    Interest000000150111
    Depreciation883555666677
    Profit before tax44544977132147123695487106137
    Tax %27%27%24%24%25%25%26%24%25%26%26%25%
    Net Profit32403858991109152406478103
    EPS in Rs₹1.85₹2.29₹2.18₹3.36₹5.71₹6.35₹5.26₹3.01₹2.32₹3.71₹4.51₹5.42

    From company filings, updated 19 Nov 2026. Consolidated figures where the company reports them. Information only, not investment advice.

    Working-capital cycle

    Debtor Days131

    +26 days since Mar 2021

    Inventory Days157

    -96 days since Mar 2021

    Days Payable48

    -80 days since Mar 2021

    Cash Conversion Cycle240

    +9 days since Mar 2021

    Working Capital Days136

    +47 days since Mar 2021

    Strengths, risks & growth

    Incorporated in 1968, Blue Jet Healthcare (earlier called Jet Chemicals Pvt Ltd) is a pharmaceutical and healthcare ingredient & intermediate company and the first manufacturer of saccharin and its salts (artificial sweeteners) in India. [1]

    Strengths

    • Company is almost debt free.
    • Company is expected to give good quarter
    • Company has a good return on equity (ROE) track record: 3 Years ROE 23.8%

    Risks

    None flagged by the checklist.

    Compounded Sales Growth

    10 Years
    —
    5 Years
    +14%
    3 Years
    +10%
    TTM
    -7%

    Compounded Profit Growth

    10 Years
    —
    5 Years
    +12%
    3 Years
    +15%
    TTM
    -19%

    Stock Price CAGR

    10 Years
    —
    5 Years
    —
    3 Years
    +10%
    1 Year
    -9%

    Return on Equity

    10 Years
    —
    5 Years
    +26%
    3 Years
    +24%
    Last Year
    +20%

    Strengths and risks are a machine-generated checklist, not advice; growth is compounded annually over each period.

    Shareholding pattern

    Percentage of shares held by each category at each quarter end
    HolderDec 2025Mar 2026Jun 2026Sept 2026Change
    Promoter79.81%79.81%79.81%73.15%-6.66 pp
    FII1.14%0.89%0.40%0.81%+0.41 pp
    DII4.65%4.51%4.65%7.48%+2.83 pp
    Public14.41%14.80%15.14%18.56%+3.42 pp

    Filed with NSE for Sept 2026: promoters 73.15%, public 26.85%

    Analysts & fund holdings

    100%
    100% recommend buy
    2 analysts cover the stock
    Valuation vs Pharmaceuticals
    P/E32.3 vs 45.2
    Sector P/B6.05

    Who holds the shares, quarter by quarter

    Mutual funds 4.10% (-1.08 pp)
    Sept 25
    Dec 25
    Mar 26
    Jun 26
    Jul 26
    Sept 26
    • Promoters73.2%
    • Foreign institutions0.8%
    • Mutual funds4.1%
    • Insurance0.7%
    • Other domestic institutions2.6%
    • Retail10.0%
    • Others8.6%
    Mutual funds holding the most
    Fund% of company% of fund3-month change
    ICICI Pru Healthcare Fund1.22%1.66%-0.73 pp
    ICICI Pru Value Fund0.67%0.11%-0.02 pp
    ICICI Pru Manufacturing Fund0.65%0.96%-0.17 pp
    UTI Small Cap Fund0.43%0.84%-0.06 pp
    UTI Healthcare Fund0.23%1.58%+0.46 pp

    Scorecard

    Performance
    Low
    Valuation
    High
    Growth
    Low
    Profitability
    High
    Entry point
    Good
    Red flags
    Low

    Analyst coverage, holdings and scorecard from market data; not a recommendation by Rajat Finance.

    Risk & trend

    From 292 daily sessions to 18 Nov 2026.

    Computed

    Risk

    Volatility (1Y)
    46.4%
    Downside volatility
    43.2%
    Worst 5% of days
    4.8%
    Average of that tail
    6.6%
    Max drawdown (1Y)
    54.4%
    Below its peak
    27.7%

    Against the market

    Beta vs Nifty 50
    1.45
    Correlation
    0.42
    Relative strength (3M)
    -16.5%
    ATR (14)
    4.5%

    Return

    Return 1M
    -0.4%
    Return 3M
    -12.6%
    Return 6M
    +23.1%
    Return 1Y
    -12.1%
    vs 200-day average
    +5.6%

    Momentum

    RSI (14)
    47.4
    MACD histogram
    0.84
    Stochastic %K
    23.8
    ADX (14)
    28.6
    +DI / −DI
    22.9 / 19.7
    Money flow index
    70.4

    Participation

    Delivery (20d avg)
    49.8%
    vs its 60-day baseline
    -0.5 pts
    Volume vs 20-day
    -0.3σ
    Close vs day's VWAP
    +0.9%
    52-week position
    49 / 100

    These describe what this stock's price has already done. They are not forecasts, signals or recommendations, and a dash means the figure was withheld for want of enough history rather than being zero.

    Financial quality

    From consolidated statements to 30 Sept 2026.

    Computed

    No F-Score: it needs two reporting periods a year apart that carry both an income statement and a balance sheet, and this company's filings do not yet line up that way. The ratios below need only the one period and are unaffected.

    Free cash flow
    ₹115 Cr
    FCF yield
    1.3%
    Net debt
    -₹38 Cr
    Net debt / equity
    -0.02
    EV / sales
    8.17

    Computed from filed statements, not filed themselves. A dash means an input was absent, and the score counts only the criteria that could actually be tested.

    Corporate actions

    • dividend
      ₹1.20

      Dividend - Rs 1.20 Per Share

      11 Sept 2026
      ex-date
    • dividend
      ₹1.20

      Dividend - Rs 1.20 Per Share

      19 Sept 2025
      ex-date
    • dividend
      Not available — not reported in this filing

      Dividend - Re 1 Per Share

      17 Sept 2024
      ex-date
    • other
      Not available — not reported in this filing

      Annual General Meeting

      17 Sept 2024
      ex-date

    Company announcements

    Company Update
    Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    Compliance Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 30th September, 2026

    Insider Trading / SAST
    Closure of Trading Window

    Intimation of closure of trading window

    AGM/EGMPrice-sensitive
    Shareholder Meeting / Postal Ballot-Scrutinizer's Report

    Scrutinizer's Report and voting results for AGM

    AGM/EGMPrice-sensitive
    Shareholder Meeting / Postal Ballot-Outcome of AGM

    Outcome of 58th Annual General Meeting of the Company

    Company Update
    Announcement under Regulation 30 (LODR)-Newspaper Publication

    Intimation of Newspaper Publication of information regarding 58th Annual General Meeting through VC/Other Audio Visual Means

    Others
    Business Responsibility and Sustainability Reporting (BRSR)

    BRSR for FY 2025-26

    AGM/EGMPrice-sensitive
    Notice Of The 58Th Annual General Meeting Of Blue Jet Healthcare Limited

    Notice of Annual General Meeting scheduled to be held on September 21, 2026

    Others
    Reg. 34 (1) Annual Report.

    Annual Report pertaining to FY 2025-26

    Company Update
    Announcement under Regulation 30 (LODR)-Newspaper Publication

    Intimation of Newspaper Publication regarding 58th Annual General Meeting through Video Conferencing/Other Audio Visual Means to be held on 21st September, 2026.

    Company Update
    Announcement under Regulation 30 (LODR)-Earnings Call Transcript

    Transcript for Earnings call for the Financials Results for the quarter ended June 30, 2026

    Company Update
    Announcement under Regulation 30 (LODR)-Newspaper Publication

    Publication of Unaudited Standalone Financial results of the Company for the Quarter ended June 30, 2026

    Company Update
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

    Submission of Audio recording of earnings conference call pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

    Company Update
    Announcement under Regulation 30 (LODR)-Investor Presentation

    Investor Presentation for Financial Results for the quarter ended June 30, 2026

    Company Update
    Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/s

    As per attached file

    Corp. Action
    Outcome For Record Date Fixed For Payment Of Dividend For FY 25-26

    As per attached file

    Filed with BSE (scrip 544009); the last 45 days. Documents open at bseindia.com.

    Documents

    Documents open at BSE or the rating agency that issued them.

    Sourced from the company's NSE XBRL filing dated 5 Nov 2026 (unaudited). View the source filing. Figures are as filed and are not investment advice.

    FAQ

    Blue Jet Healthcare: common questions

    Answered from the figures on this page.

    Blue Jet Healthcare last traded at ₹518.45 (NSE, as of 18 Nov 2026). The last session moved it up 1.54%.

    Blue Jet Healthcare is valued at about ₹8,993 crore (NSE, as of 18 Nov 2026).

    Blue Jet Healthcare trades at a price-to-earnings ratio of 32.34 (NSE, as of 18 Nov 2026). The P/E compares the share price with earnings per share, so it is only comparable between companies in the same industry.

    Blue Jet Healthcare has traded between ₹325.00 and ₹647.80 over the past 52 weeks, to 18 Nov 2026. It is currently 60% of the way up that range.

    Blue Jet Healthcare (BLUEJET) is classified under Pharma on this site's screener.